Drug Profile
Efatutazone - Daiichi Sankyo
Alternative Names: CS-7017; Inolitazone; RS-5444Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Alliance for Clinical Trials in Oncology; Daiichi Sankyo Company; National Cancer Institute (USA)
- Class Antineoplastics; Benzimidazoles; Thiazolidinediones
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Liposarcoma; Non-small cell lung cancer; Thyroid cancer
Most Recent Events
- 15 Apr 2023 Daiichi Sankyo and Alliance for Clinical Trials in Oncology completes a phase II trial in Thyroid cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02152137)
- 30 Jan 2018 Daiichi Sankyo and Alliance for Clinical Trials in Oncology re-initiates enrolment in a phase II trial in Thyroid cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02152137)
- 31 Jul 2013 Discontinued - Phase-I for Colorectal cancer in Japan (PO)